{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:23:53Z","timestamp":1792844633642,"version":"4.5.0"},"reference-count":32,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,10,28]]},"published-print":{"date-parts":[[2025,1]]},"DOI":"10.2967\/jnumed.124.268441","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T21:15:26Z","timestamp":1735938926000},"page":"54-60","source":"Crossref","is-referenced-by-count":39,"title":["Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET\u2014An International Multicenter Retrospective Study"],"prefix":"10.2967","volume":"66","author":[{"given":"Lena M.","family":"Unterrainer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honest","family":"Ndlovu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias R.","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"2025010313152055000_66.1.54.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"2025010313152055000_66.1.54.2","doi-asserted-by":"crossref","first-page":"TPS383","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS383","article-title":"ARASENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"36","author":"Smith","year":"2018","journal-title":"J Clin Oncol."},{"key":"2025010313152055000_66.1.54.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900"},{"key":"2025010313152055000_66.1.54.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2025010313152055000_66.1.54.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03488"},{"key":"2025010313152055000_66.1.54.6","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1200\/JCO.2019.37.15_suppl.5048","article-title":"ARCHES: efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol."},{"key":"2025010313152055000_66.1.54.7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol."},{"key":"2025010313152055000_66.1.54.8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol."},{"key":"2025010313152055000_66.1.54.9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol."},{"key":"2025010313152055000_66.1.54.10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol."},{"key":"2025010313152055000_66.1.54.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262120"},{"key":"2025010313152055000_66.1.54.12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol."},{"key":"2025010313152055000_66.1.54.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1050"},{"key":"2025010313152055000_66.1.54.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2025010313152055000_66.1.54.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242057"},{"key":"2025010313152055000_66.1.54.16","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s00259-016-3350-4","article-title":"Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons","volume":"43","author":"Evangelista","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025010313152055000_66.1.54.17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41391-019-0151-4","article-title":"Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials","volume":"22","author":"Mota","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2025010313152055000_66.1.54.18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bju.13160","article-title":"Bone scan index predicts outcome in patients with metastatic hormone\u2010sensitive prostate cancer","volume":"117","author":"Poulsen","year":"2016","journal-title":"BJU Int."},{"key":"2025010313152055000_66.1.54.19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12885-016-2176-6","article-title":"Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases","volume":"16","author":"Miyoshi","year":"2016","journal-title":"BMC Cancer."},{"key":"2025010313152055000_66.1.54.20","doi-asserted-by":"crossref","first-page":"663631","DOI":"10.3389\/fonc.2021.663631","article-title":"Feasibility of different tumor delineation approaches for 18F-PSMA-1007 PET\/CT imaging in prostate cancer patients","volume":"11","author":"Mittlmeier","year":"2021","journal-title":"Front Oncol."},{"key":"2025010313152055000_66.1.54.21","doi-asserted-by":"crossref","first-page":"205.e17","DOI":"10.1016\/j.urolonc.2022.12.006","article-title":"A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the bone lesion detection of conventional imaging and 18F-PSMA-PET\/CT","volume":"41","author":"Bodar","year":"2023","journal-title":"Urol Oncol."},{"key":"2025010313152055000_66.1.54.22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1186\/s12885-020-07192-7","article-title":"Clinical impact of PSMA PET\/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study","volume":"20","author":"Donswijk","year":"2020","journal-title":"BMC Cancer."},{"key":"2025010313152055000_66.1.54.23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.euf.2021.01.016","article-title":"The role of PSMA PET\/CT and PET\/MRI in the initial staging of prostate cancer","volume":"7","author":"Murthy","year":"2021","journal-title":"Eur Urol Focus."},{"key":"2025010313152055000_66.1.54.24","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1007\/s00259-017-3752-y","article-title":"The accuracy of 68Ga-PSMA PET\/CT in primary lymph node staging in high-risk prostate cancer","volume":"44","author":"\u00d6bek","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025010313152055000_66.1.54.25","unstructured":"Fizazi K . APCCC 2022: when low-volume on conventional imaging goes into high-volume on next-generation imaging in mHSPC: treat like low volume. Urotoday website. https:\/\/www.urotoday.com\/conference-highlights\/apccc-2022\/136802-apccc-2022-when-low-volume-on-conventional-imaging-goes-into-high-volume-on-next-generation-imaging-in-mhspc-treat-like-low-volume.html. Updated September 6, 2022. Accessed December 4, 2024."},{"key":"2025010313152055000_66.1.54.26","unstructured":"Fanti S . APCCC 2022: how to interpret and confirm lesions positive on PSMA PET but with no correlation on CT? Urotoday website. https:\/\/www.urotoday.com\/conference-highlights\/apccc-2022\/136832-apccc-2022-how-to-interpret-and-confirm-lesions-positive-on-psma-pet-but-with-no-correlation-on-ct.html. Updated March 30, 2023. Accessed December 4, 2024."},{"key":"2025010313152055000_66.1.54.27","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","article-title":"Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation","volume":"48","author":"Arnfield","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025010313152055000_66.1.54.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.215434"},{"key":"2025010313152055000_66.1.54.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265916"},{"key":"2025010313152055000_66.1.54.30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eururo.2022.10.005","article-title":"More accurate imaging is not stage migration: time to move from \u201cHubble\u201d to \u201cWebb\u201d in hormone-sensitive prostate cancer","volume":"83","author":"Ayati","year":"2023","journal-title":"Eur Urol."},{"key":"2025010313152055000_66.1.54.31","doi-asserted-by":"crossref","first-page":"e222010","DOI":"10.1148\/radiol.222010","article-title":"A prognostic risk score for prostate cancer based on PSMA PET\u2013derived organ-specific tumor volumes","volume":"307","author":"Seifert","year":"2023","journal-title":"Radiology."},{"key":"2025010313152055000_66.1.54.32","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T21:17:36Z","timestamp":1735939056000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,3]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.2967\/jnumed.124.268441"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268441","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}